PARABOLIC DRUGS LIMITED
FIRST QUARTER RESULTS
Q1 FY 2013
PARABOLIC
DRUGS has declared its first quarter results for Q/e June 2012
and for Year ending March,2012.
Net
Sales for Q1 FY 12 stands at Rs.305.20 Cr; up by 14.72% from Q4 FY 12 (Rs.266.05 Cr); and up by
63.92% from Q1 FY 12 (Rs.186.19 Cr).
Total
Expenditure for Q1 FY 12
stands at Rs.276.04 Cr; up by 14.86%
from Q4 FY 12 (Rs.240.32 Cr); and up by 78.3% from Q1 FY 12 (Rs.154.82 Cr). The
expenditure has grown more than proportionately compared to Sales. Of this
Material cost itself has registered Huge increase of 37% and other expenses 39%
YoY.
Profit
before Interest, Dep. & Taxes for Q1 FY 12 stands at Rs.29.16 Cr; up by 13.33% from Q4
FY 12 (Rs.25.73 Cr); and down by -7.04% from Q1 FY 12 (Rs.31.37 Cr). Because of
heavier Expenditure, Profits YoY have come down.
Net
Profit for Q1 FY 12 stands at Rs.9.76 Cr; up by 8.2% from Q4 FY 12 (Rs.9.02
Cr); and down by -35.7% from Q1 FY 12 (Rs.15.18 Cr). Net Profit is also down
36% YoY because of heavier growth in expenditure.
Diluted
EPS for Q1 FY 12
stands at Rs.1.58; compared to Rs.1.46 in Q4 FY 12; and Rs.2.45 in Q1 FY 12.
Public
Shareholding stands at 60.77% in the company.
Net
Profit(+)/Loss(-) from Ordinary Activities after tax for FY 2011-12 (totally) was Rs.51.21 Cr and the Annual EPs
was Rs.8.27.
52 week high/low price : Rs.42.00/16.25;
Current Price : Rs.22.80.
Considering the increase in its Sales every Quarter, the
company may put up better performances in coming quarters. However, its
profitability depends on introducing more
and more new products which are said to be in the pipeline and marketing them
well. Thus, PDL's Future appears promising
RESULTS TABLE
(In Lakhs.Rs)
|
PARABOLIC DRUGS
|
30-Jun-12
|
QoQ % Dif
|
31-Mar-12
|
YoY % Dif
|
30-Jun-11
|
31-Dec-11
|
30-Sep-11
|
|
Net Sales
|
30520
|
14.72
|
26605
|
63.92
|
18619
|
27089
|
19559
|
|
Total Expdr
|
27604
|
14.86
|
24032
|
78.3
|
15482
|
23928
|
16378
|
|
Profit before Interest, Dep. & Taxes
|
2916
|
13.33
|
2573
|
-7.04
|
3137
|
3161
|
3181
|
|
Net Profit
|
976
|
8.2
|
902
|
-35.7
|
1518
|
1282
|
1438
|
|
Diluted EPS
|
1.58
|
8.22
|
1.46
|
-35.51
|
2.45
|
2.07
|
2.32
|
|
Net Sales
|
30520
|
14.72
|
26605
|
63.92
|
18619
|
27089
|
19559
|
|
Changes in inventories of FG/ WIP / SIT
|
-2487
|
-310.76
|
1180
|
-61.64
|
-6483
|
-2707
|
-1759
|
|
Materials consumed
|
27149
|
36.62
|
19872
|
36.86
|
19837
|
13194
|
15724
|
|
Purchases of SIT
|
-
|
-
|
-
|
10896
|
-
|
||
|
Employee benefits
|
510
|
-16.12
|
608
|
7.82
|
473
|
593
|
572
|
|
Depreciation
|
1209
|
55.4
|
778
|
56
|
775
|
776
|
776
|
|
Other expenses
|
1223
|
-23.27
|
1594
|
38.98
|
880
|
1176
|
1065
|
|
Total expenses
|
27604
|
14.86
|
24032
|
78.3
|
15482
|
23928
|
16378
|
|
Profit before tax
|
1346
|
10.24
|
1221
|
-32.4
|
1991
|
1696
|
1891
|
|
Tax Expenses
|
370
|
15.99
|
319
|
-21.78
|
473
|
414
|
453
|
|
Net Profit
|
976
|
8.2
|
902
|
-35.7
|
1518
|
1282
|
1438
|
|
Face Value (Rs )
|
10
|
0
|
10
|
0
|
10
|
10
|
10
|
|
Paid-up Equity
|
6189
|
0
|
6189
|
0
|
6189
|
6189
|
6189
|
|
Diluted EPS
|
1.58
|
8.22
|
1.46
|
-35.51
|
2.45
|
2.07
|
2.32
|
|
Public Shareholding (%)
|
60.77
|
-0.02
|
60.78
|
-1.68
|
61.81
|
60.83
|
61.31
|
FY 2011-12 results
Description : FY12 NONCON (In Lakhs of Rs)
Net Sales : 91634
Total Expenditure : 79784
Profit from Operations : 13058
Profit before Interest & Exceptional Items : 13058
Interest : 6414
Profit after Interest but before Exceptional Items : 6644
Profit before tax : 6644
Tax Expense : 1523
Net Profit : 5121
Face Value (in Rs.) : 10
Paid-up Equity Share Capital : 6189
Public Shareholding (%) : 60.78
ABOUT THE COMPANY
Parabolic Drugs Ltd., incorporated in 1996, is promoted
by professionally qualified first generation entrepreneurs. It is engaged in
manufacturing, including contract manufacturing, of APIs and API intermediates
for domestic and international markets, including regulated markets. It
manufactures Semi Synthetic Penicillin (“SSP”) and Cephalosporin range of
antibiotics, whereby the product portfolio comprises 44 APIs and 7 API
intermediates. The company has two manufacturing facilities located at
Derabassi, Punjab and Panchkula, Haryana. It also has a custom synthesis and
R&D centre at Barwala, Haryana, which started operations in January 2010.
Proposed facilities include a manufacturing facility for non-antibiotic
products at Chachrauli, Derabassi and another custom synthesis and manufacturing
site at Panchkula being set up by PDL’s subsidiary.
NEWS
ABOUT PDL
2012 : Parabolic
Drugs initiates production at its Lalru facility for lifestyle drugs and non
antibiotics.The company expects to launch several molecules with a total
production pipeline of 17 molecules in a
3 year period as per its Q3 FY 12 results. It is developing its distributor and
stockiest network in over 20 states.
2011 : (1) Parabolic Drugs gets Japanese nod for
Cephalosporin Drugs (2) Parabolic Drugs receives Certificate of
Suitability for Cefixime molecule from EU
(3) Parabolic Drugs 9M FY11 net
profit up 65.6% to Rs. 37.30 Crores,Sales up 24.4% to Rs. 466.04
Crores(February 2nd,2011) (4) Parabolic Drugs Completes first phase of
Expansion
2010 : (1) PDL
now gets EU-GMP accreditation(July 12th,2010)
(2) Barwala Research and
Development centre inaugurated
2009 : (1) WHO
-GMP certificate for Cephalosporin facility(August 24th,2009) (2) ISO
14001 certification for PDL(August 6th,2010)
* *
* E N D *
* *
No comments:
Post a Comment